Human Immunology News

Human Immunology News is an online publication and email newsletter for researchers studying the human immune system.

T Cells Isolated from G-CSF-Treated Multiple Myeloma Patients Are Suitable for the Generation of BCMA-Directed CAR-T Cells

June 28, 2022

[Molecular Therapy-Methods & Clinical Development] Scientists showed that autologous stem cell transplantation apheresis products were a suitable source of T cells for anti-B-cell maturation antigen (BCMA) CAR-T cell manufacture.

Network-Based Machine Learning Approach to Predict Immunotherapy Response in Cancer Patients

June 28, 2022

[Nature Communications] The authors curated more than 700 immune checkpoint inhibitor (ICI)-treated patient samples with clinical outcomes and transcriptomic data, and observed that NetBio-based predictions accurately predicted ICI treatment responses in three different cancer types — melanoma, gastric cancer, and bladder cancer.

High-Dimensional Profiling Reveals Tc17 Cell Enrichment in Active Crohn’s Disease and Identifies a Potentially Targetable Signature

June 28, 2022

[Nature Communications] Investigators characterized the peripheral blood and intestinal tissue of Crohn’s disease patients with flow and mass cytometry and revealed a strong increase of Tc17 cells in active disease, mainly due to induction of conventional T cells.

Immune Organoids: From Tumor Modeling to Precision Oncology

June 28, 2022

[Trends in Cancer] Scientists review the different methodologies for developing a more holistic patient-derived tumor organoid platform and for modeling the native immune tumor microenvironment.

Charting Roadmaps towards Novel and Safe Synergistic Immunotherapy Combinations

June 28, 2022

[Nature Cancer] The authors focus on recent developments in immunotherapy combinations and reflect on how combinations should be optimized to maximize the impact of immunotherapy in clinical oncology.

Veloxis Pharmaceuticals Announces Dosing of the First Patient by Partner Xenikos in the Global Phase III Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute...

June 28, 2022

[Veloxis Pharmaceuticals] Veloxis Pharmaceuticals announced dosing of the first patient by its partner, Xenikos, in a Phase III clinical study designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV SR-aGVHD following allogeneic hematopoietic stem cell transplant.

Xenikos Enrolls First Patient in Global Pivotal Phase III Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

June 27, 2022

[Xenikos B.V.] Xenikos B.V. announced the enrolment of the first patient in a global pivotal Phase III clinical study designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplant.

cBAF Complex Components and MYC Cooperate Early in CD8+ T Cell Fate

June 24, 2022

[Nature] Using a CRISPR-based screen for negative regulators of memory T cell generation in vivo, the authors identified multiple components of the mammalian canonical BRG1/BRM-associated factor (cBAF).

Art v 1 IgE Epitopes of Patients and Humanized Mice Are Conformational

June 24, 2022

[Journal of Allergy and Clinical Immunology] Researchers characterized IgE epitopes of Art v 1–sensitized patients and humanized mice for molecular immunotherapy of mugwort allergy.

Favorable Immune Checkpoint Inhibitor Outcome of Patients with Melanoma and NSCLC Harboring FAT1 Mutations

June 24, 2022

[npj Precision Oncology] The authors investigated the association of FAT atypical cadherin 1 (FAT1) mutations with immune checkpoint inhibitor response and outcome.

Cancer Immunohistogram Representing Cancer-Immunity Cycle by Immunohistochemistry Predicts the Efficacy of Immune Checkpoint Inhibitors in Urological Cancer Patients

June 24, 2022

[Scientific Reports] Scientists developed an immunohistogram representing an individual cancer-immunity cycle based on immunohistochemical analyses and evaluated its ability to predict the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma and renal cell carcinoma.

Single-Cell Transcriptomics and Surface Epitope Detection in Human Brain Epileptic Lesions Identifies Pro-inflammatory Signaling

June 24, 2022

[Nature Neuroscience] Investigators used single-cell cellular indexing of transcriptomes and epitopes by sequencing to reveal the immunotranscriptome of surgically resected epileptic lesion tissues. Their approach uncovered a pro-inflammatory microenvironment, including extensive activation of microglia and infiltration of other pro-inflammatory immune cells.

Each issue of Human Immunology News provides up-to-date coverage of the latest news in immunology research performed using human cells or subjects. Our expert editors hand-pick recent research papers and review articles from relevant high-impact peer-reviewed journals on topics including immunotherapy, autoimmunity, adaptive, and innate immunity in humans. We also feature news on clinical trials, award announcements, and funding opportunities.